

29 January 2025

RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")

New Supply Agreement

RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon™), announces supply agreement within its Medical Device and Components business unit with initial annual value of over £500,000.

Further to the textile processing project announced on 24 July last year, RUA has now entered a multi-year supply contract with the global customer. The agreement covers two product lines, unit volumes and unit pricing. The revenue expected during the current calendar year is anticipated to grow over time with a potential value over a five-year period of £3.3 million. This new contract represents a six-fold increase on the level of business undertaken for the customer prior to commencing work on the project.

Bill Brown, CEO of RUA Life Sciences, stated: *"The RUA Quality, R&D and Production teams worked closely with our global customer to exceed their expectations during the project phase which resulted with this long term partnership."*

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

For further information contact:

RUA Life Sciences

Bill Brown, CEO
Lachlan Smith, CFO

Tel: +44 (0)1294 317073
Tel: +44 (0)1294 317073

Cavendish Capital Markets
Limited

(Nominated Adviser and Broker)

Giles Balleny/Dan Hodgkinson (Corporate Finance)
Charlie Combe (Broking)
Michael Johnson (Sales)

Tel: +44 (0)20 7220 0500

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-Eon™, the world's leading long-term implantable polyurethane. Whether it is licensing Elast-Eon™, manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

RUA Contract Manufacture: End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.

RUA Biomaterials: Licensor of Elast-Eon™ polymers to the medical device industry.

RUA Vascular: Commercialisation of open surgical vascular grafts and patches

RUA Structural Heart:

Development of polymeric leaflet systems for heart valves.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lse.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTFZGZMVRKGKZM